News

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO.

“We are excited to welcome Dave to our leadership team,” said McCoy. “His deep expertise in pharmaceutical manufacturing and global operations will be instrumental as we continue to bring our Petersburg facility online and expand access to essential medicines.”

Sehgal has nearly 30 years of experience in the pharmaceutical industry, having held leadership roles in the vaccines, biologics and small molecule manufacturing space. He also has significant experience in technical services, quality and process development. Dr. Sehgal succeeds Jay Benson.

“I am thrilled to join Civica at this time in the company’s history,” said Sehgal. “I look forward to leading the team that will bring high-quality, essential generic medicines, manufactured in the United Sates to patients who need them.”

Dr. Sehgal resides in Raleigh, NC and will be working closely with the Civica team at the company’s manufacturing facility in Petersburg, Va. The 140,000 square foot, state-of-the-art facility currently employs more than 200 skilled workers, with plans to hire another 60 employees by the end of 2025. The facility has the capacity to manufacture 90 million vials, 50 million syringes and 120 million pre-filled pens of generic sterile injectable medicines every year. The facility is in the final stages of certification by regulatory authorities and will be producing medicines for distribution in 2026.

Prior to joining Civica, Dr. Sehgal was the Vice President and Global Processing Engineering Head at CSL-Behring in Holly Springs, North Carolina. In that role, he led a team of 500 scientists and engineers across four global sites in support of all CSL-Behring products. Before CSL-Behring, Sehgal held leadership positions at FUJIFILM Diosynth Biotechnologies, Seqirus, Novartis, and Merck. Sehgal earned a bachelor’s, master’s, and doctoral degree in chemical engineering from NC State University.

This appointment reflects Civica’s continued commitment to operational excellence and its mission to make quality generic medicines accessible and affordable for all.

 

Read more here.

Recent News

08/26/2025

Activation Capital Names Michael Steele as President and CEO

The Virginia Biotechnology Research Partnership Authority (doing business as Activation Capital) announced today that it has appointed Michael Steele as president and chief executive officer. Steele succeeds Robert Ward, who has served as interim CEO since July 2024 during a period of rapid growth for the life sciences ecosystem development organization. Steele comes to Activation

08/25/2025

Danforth Advisors Acquires PharmaDirections

Danforth Advisors LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization. Founded in 2003, PharmaDirections was a pioneer of the virtual drug development model. The company brings veteran program leaders and more than 150 specialists to support strategic planning and

08/22/2025

ivWatch Technology Linked to Major Reduction in Severe IV Injuries in Newborns Over Four-Year Study

A study published this month in The BMJ (British Medical Journal) analyzed the use of optical sensor technology from ivWatch, the U.S.-based IV safety company, in the early detection of peripheral intravenous infiltration or extravasation (PIVIE) events in neonates. Presenting a comparative evaluation between conventional observational methods and continuous sensor-based monitoring, the study offers insights